Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
30.56
+1.39 (4.78%)
At close: Apr 28, 2026, 4:00 PM EDT
30.45
-0.11 (-0.36%)
After-hours: Apr 28, 2026, 6:50 PM EDT
Beam Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Beam Therapeutics stock have an average target of 50.75, with a low estimate of 21 and a high estimate of 80. The average target predicts an increase of 66.07% from the current stock price of 30.56.
Analyst Consensus: Buy
* Price targets were last updated on Mar 26, 2026.
Analyst Ratings
The average analyst rating for Beam Therapeutics stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 4 |
| Buy | 5 | 5 | 6 | 7 | 5 | 5 |
| Hold | 2 | 2 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 14 | 16 | 14 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $64 → $68 | Strong Buy | Maintains | $64 → $68 | +122.51% | Mar 26, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $22 → $26 | Hold | Maintains | $22 → $26 | -14.92% | Feb 25, 2026 |
| Wedbush | Wedbush | Buy Maintains $57 → $65 | Buy | Maintains | $57 → $65 | +112.70% | Feb 25, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $74 | Strong Buy | Initiates | $74 | +142.15% | Feb 20, 2026 |
| Bernstein | Bernstein | Buy Maintains $37 → $41 | Buy | Maintains | $37 → $41 | +34.16% | Jan 21, 2026 |
Financial Forecast
Revenue This Year
48.38M
from 139.74M
Decreased by -65.38%
Revenue Next Year
64.71M
from 48.38M
Increased by 33.77%
EPS This Year
-4.70
from -0.81
EPS Next Year
-4.80
from -4.70
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 115.5M | 191.5M | ||||||
| Avg | 48.4M | 64.7M | ||||||
| Low | 34.3M | 33.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -17.3% | 295.8% | ||||||
| Avg | -65.4% | 33.8% | ||||||
| Low | -75.5% | -31.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.93 | -3.78 | ||||||
| Avg | -4.70 | -4.80 | ||||||
| Low | -5.19 | -6.06 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.